Swiss-German radiopharmaceutical company Nuclidium closed a $98 million Series B financing to accelerate development and production of its copper-61 and copper-67 radiotheranostic agents for cancer diagnosis and treatment. The funding round, led by multiple global investors, supports the company's strategy of combining diagnostic and therapeutic isotopes to improve clinical outcomes. Early clinical data suggest their platform may outperform existing radiotheranostic standards.